Coronary artery bypass grafting in acute coronary syndromes: modern indications and approaches.
Journal
Current opinion in cardiology
ISSN: 1531-7080
Titre abrégé: Curr Opin Cardiol
Pays: United States
ID NLM: 8608087
Informations de publication
Date de publication:
12 Aug 2024
12 Aug 2024
Historique:
medline:
28
8
2024
pubmed:
28
8
2024
entrez:
28
8
2024
Statut:
aheadofprint
Résumé
Acute coronary syndromes (ACS) are a leading cause of morbidity and mortality worldwide, with approximately 1.2 million hospitalizations annually in the U.S. This review aims to explore the contemporary evidence regarding revascularization strategies, including percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG), in ACS patients. It also addresses the unresolved questions concerning the optimal procedural aspects of surgery and antithrombotic therapy for secondary prevention postsurgery. Recent studies highlight that while PCI is generally preferred for its timeliness in high-risk non-ST-elevation ACS (NSTE-ACS) patients, CABG offers a benefit in terms of cardiovascular events in those with multivessel disease, particularly in the presence of diabetes and higher coronary disease complexity. For ST-elevation myocardial infarction (STEMI), CABG is less frequently utilized due to the preference for primary PCI, but it remains crucial for patients with complex anatomy or failed PCI. Furthermore, the optimal timing and type of antiplatelet therapy post-CABG remain controversial, with current evidence supporting the use of dual antiplatelet therapy (DAPT) to reduce ischemic events but necessitating careful management to balance bleeding risks. In patients with ACS, the choice between PCI and CABG depends on the complexity of coronary disease and patient comorbidities. CABG is particularly beneficial for multivessel disease in NSTE-ACS and specific STEMI cases where PCI is not feasible. The management of antiplatelet therapy postsurgery requires a nuanced approach to minimize bleeding risks while preventing thrombotic complications. Further randomized clinical trials are needed to solidify these findings and guide clinical practice.
Identifiants
pubmed: 39195561
doi: 10.1097/HCO.0000000000001172
pii: 00001573-990000000-00167
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2024 The Author(s). Published by Wolters Kluwer Health, Inc.
Références
Martin SS, Aday AW, Almarzooq ZI, et al. 2024 Heart Disease and Stroke Statistics: a report of US and Global Data From the American Heart Association. Circulation 2024; 149:e347–e913.
Byrne RA, Rossello X, Coughlan JJ, et al. 2023 ESC Guidelines for the management of acute coronary syndromes. Eur Heart J 2023; 44:3720–3826.
Head SJ, Milojevic M, Daemen J, et al. Mortality after coronary artery bypass grafting versus percutaneous coronary intervention with stenting for coronary artery disease: a pooled analysis of individual patient data. Lancet 2018; 391:939–948.
Sabatine MS, Bergmark BA, Murphy SA, et al. Percutaneous coronary intervention with drug-eluting stents versus coronary artery bypass grafting in left main coronary artery disease: an individual patient data meta-analysis. Lancet 2021; 398:2247–2257.
Biscaglia S, Guiducci V, Escaned J, et al. Complete or culprit-only PCI in older patients with myocardial infarction. N Engl J Med 2023; 389:889–898.
Diletti R, den Dekker WK, Bennett J, et al. Immediate versus staged complete revascularisation in patients presenting with acute coronary syndrome and multivessel coronary disease (BIOVASC): a prospective, open-label, noninferiority, randomised trial. Lancet 2023; 401:1172–1182.
Patlolla SH, Kanwar A, Cheungpasitporn W, et al. Temporal trends, clinical characteristics, and outcomes of emergent coronary artery bypass grafting for acute myocardial infarction in the United States. J Am Heart Assoc 2021; 10:e020517.
Writing Committee M, Lawton JS, Tamis-Holland JE, et al. 2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol 2022; 79:e21–e129.
Grothusen C, Friedrich C, Loehr J, et al. Outcome of stable patients with acute myocardial infarction and coronary artery bypass surgery within 48 hours: a single-center, retrospective experience. J Am Heart Assoc 2017; 6:e005498-17.
Thielmann M, Wendt D, Slottosch I, et al. Coronary artery bypass graft surgery in patients with acute coronary syndromes after primary percutaneous coronary intervention: a current report from the North-Rhine Westphalia Surgical Myocardial Infarction Registry. J Am Heart Assoc 2021; 10:e021182.
Hochman JS, Sleeper LA, Webb JG, et al. Early revascularization in acute myocardial infarction complicated by cardiogenic shock. SHOCK Investigators. Should we emergently revascularize occluded coronaries for cardiogenic shock. N Engl J Med 1999; 341:625–634.
Hochman JS, Sleeper LA, White HD, et al. One-year survival following early revascularization for cardiogenic shock. JAMA 2001; 285:190–192.
Hochman JS, Sleeper LA, Webb JG, et al. Early revascularization and long-term survival in cardiogenic shock complicating acute myocardial infarction. JAMA 2006; 295:2511–2515.
Smilowitz NR, Alviar CL, Katz SD, Hochman JS. Coronary artery bypass grafting versus percutaneous coronary intervention for myocardial infarction complicated by cardiogenic shock. Am Heart J 2020; 226:255–263.
Ronco D, Corazzari C, Matteucci M, et al. Effects of concomitant coronary artery bypass grafting on early and late mortality in the treatment of postinfarction mechanical complications: a systematic review and meta-analysis. Ann Cardiothorac Surg 2022; 11:210–225.
Massimi G, Matteucci M, Kowalewski M, et al. Surgical treatment of postinfarction papillary muscle rupture: systematic review and meta-analysis. Ann Cardiothorac Surg 2022; 11:252–260.
Massimi G, Ronco D, De Bonis M, et al. Surgical treatment for postinfarction papillary muscle rupture: a multicentre study. Eur J Cardiothorac Surg 2022; 61:469–476.
Sabik JF, Mehaffey JH, Badhwar V, et al. Multiarterial vs single-arterial coronary surgery: 10-year follow-up of 1 million patients. Ann Thorac Surg 2024; 117:780–788.
Taggart DP, Benedetto U, Gerry S, et al. Bilateral versus Single Internal-Thoracic-Artery Grafts at 10 Years. N Engl J Med 2019; 380:437–446.
Gaudino M, Di Franco A, Rahouma M, et al. Unmeasured confounders in observational studies comparing bilateral versus single internal thoracic artery for coronary artery bypass grafting: a meta-analysis. J Am Heart Assoc 2018; 7:e008010.
Liakopoulos OJ, Schlachtenberger G, Wendt D, et al. Early clinical outcomes of surgical myocardial revascularization for acute coronary syndromes complicated by cardiogenic shock: a report from the North-Rhine-Westphalia Surgical Myocardial Infarction Registry. J Am Heart Assoc 2019; 8:e012049.
Grieshaber P, Oster L, Schneider T, et al. Total arterial revascularization in patients with acute myocardial infarction - feasibility and outcomes. J Cardiothorac Surg 2018; 13:2.
Hwang B, Williams ML, Tian DH, et al. Coronary artery bypass surgery for acute coronary syndrome: a network meta-analysis of on-pump cardioplegic arrest, off-pump, and on-pump beating heart strategies. J Card Surg 2022; 37:5290–5299.
Davierwala PM, Leontyev S, Verevkin A, et al. Temporal trends in predictors of early and late mortality after emergency coronary artery bypass grafting for cardiogenic shock complicating acute myocardial infarction. Circulation 2016; 134:1224–1237.
Rastan AJ, Eckenstein JI, Hentschel B, et al. Emergency coronary artery bypass graft surgery for acute coronary syndrome: beating heart versus conventional cardioplegic cardiac arrest strategies. Circulation 2006; 114: (1 Suppl): I477–I485.
Gaudino M, Glineur D, Mazza A, et al. Long-term survival and quality of life of patients undergoing emergency coronary artery bypass grafting for postinfarction cardiogenic shock. Ann Thorac Surg 2016; 101:960–966.
Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361:1045–1057.
Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357:2001–2015.
Franchi F, Angiolillo DJ. Novel antiplatelet agents in acute coronary syndrome. Nat Rev Cardiol 2015; 12:30–47.
Capodanno D, Bhatt DL, Gibson CM, et al. Bleeding avoidance strategies in percutaneous coronary intervention. Nat Rev Cardiol 2022; 19:117–132.
Fox KA, Mehta SR, Peters R, et al. Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome: the Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) Trial. Circulation 2004; 110:1202–1208.
Smith PK, Goodnough LT, Levy JH, et al. Mortality benefit with prasugrel in the TRITON-TIMI 38 coronary artery bypass grafting cohort: risk-adjusted retrospective data analysis. J Am Coll Cardiol 2012; 60:388–396.
Hansson EC, Jideus L, Aberg B, et al. Coronary artery bypass grafting-related bleeding complications in patients treated with ticagrelor or clopidogrel: a nationwide study. Eur Heart J 2016; 37:189–197.
Purkayastha S, Athanasiou T, Malinovski V, et al. Does clopidogrel affect outcome after coronary artery bypass grafting? A meta-analysis. Heart 2006; 92:531–532.
Held C, Asenblad N, Bassand JP, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery: results from the PLATO (Platelet Inhibition and Patient Outcomes) trial. J Am Coll Cardiol 2011; 57:672–684.
Gherli R, Mariscalco G, Dalen M, et al. Safety of preoperative use of ticagrelor with or without aspirin compared with aspirin alone in patients with acute coronary syndromes undergoing coronary artery bypass grafting. JAMA Cardiol 2016; 1:921–928.
Sousa-Uva M, Head SJ, Milojevic M, et al. 2017 EACTS Guidelines on perioperative medication in adult cardiac surgery. Eur J Cardiothorac Surg 2018; 53:5–33.
Angiolillo DJ, Firstenberg MS, Price MJ, et al. Bridging antiplatelet therapy with cangrelor in patients undergoing cardiac surgery: a randomized controlled trial. JAMA 2012; 307:265–274.
Rossini R, Masiero G, Fruttero C, et al. Antiplatelet therapy with cangrelor in patients undergoing surgery after coronary stent implantation: a real-world bridging protocol experience. TH Open 2020; 4:e437–e445.
Wallentin L. P2Y (12) inhibitors: differences in properties and mechanisms of action and potential consequences for clinical use. Eur Heart J 2009; 30:1964–1977.
Gurbel PA, Bliden KP, Butler K, et al. Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study. Circulation 2009; 120:2577–2585.
Ranucci M, Colella D, Baryshnikova E, et al. Effect of preoperative P2Y12 and thrombin platelet receptor inhibition on bleeding after cardiac surgery. Br J Anaesth 2014; 113:970–976.
Kwak YL, Kim JC, Choi YS, et al. Clopidogrel responsiveness regardless of the discontinuation date predicts increased blood loss and transfusion requirement after off-pump coronary artery bypass graft surgery. J Am Coll Cardiol 2010; 56:1994–2002.
Storey RF, Bliden KP, Ecob R, et al. Earlier recovery of platelet function after discontinuation of treatment with ticagrelor compared with clopidogrel in patients with high antiplatelet responses. J Thromb Haemost 2011; 9:1730–1737.
Malm CJ, Alfredsson J, Erlinge D, et al. Dual or single antiplatelet therapy after coronary surgery for acute coronary syndrome (TACSI trial): rationale and design of an investigator-initiated, prospective, multinational, registry-based randomized clinical trial. Am Heart J 2023; 259:1–8.
Musleh G, Dunning J. Does aspirin 6 h after coronary artery bypass grafting optimise graft patency? Interact Cardiovasc Thorac Surg 2003; 2:413–415.
Schunkert H, Boening A, von Scheidt M, et al. Randomized trial of ticagrelor vs. aspirin in patients after coronary artery bypass grafting: the TiCAB trial. Eur Heart J 2019; 40:2432–2440.
Sandner S, Redfors B, Angiolillo DJ, et al. Association of dual antiplatelet therapy with ticagrelor with vein graft failure after coronary artery bypass graft surgery: a systematic review and meta-analysis. JAMA 2022; 328:554–562.